SpringerLink
Log in

Meta-analysis of antiplatelet therapy for IgA nephropathy

  • ORIGINAL ARTICLE
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Antiplatelet agents have been widely used in the management of immunoglobulin A (IgA) nephropathy in the Japanese population. To systematically evaluate the effects of antiplatelet agents for IgA nephropathy, we conducted a meta-analysis of the published studies.

Methods

Data sources consisted of MEDLINE, EMBASE, the Cochrane Library, Ityu-shi (Japanese medical database), and bibliographies from the studies. The quality of the studies was evaluated from the intention to treat analysis and allocation concealment, as well as by the Jadad method. Meta-analyses were performed on the outcomes of proteinuria and renal function.

Results

Seven articles met the predetermined inclusion criteria. The use of antiplatelet agents showed statistically significant effects on proteinuria and renal function. The pooled risk ratio for proteinuria was 0.61 (95% confidence intervals (CI) 0.39–0.94) and for renal function it was 0.74 (95% CI 0.63–0.87).

Conclusions

Antiplatelet agents resulted in reduced proteinuria and protected renal function in patients with IgA nephropathy. However, studies of high-quality design were rare, and most studies assessed surrogate outcomes. More properly designed studies are needed to reach a definitive assessment of this matter.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. JV Donadio JP Grande (2002) ArticleTitleIgA nephropathy N Engl J Med 347 738–48 Occurrence Handle12213946 Occurrence Handle10.1056/NEJMra020109 Occurrence Handle1:CAS:528:DC%2BD38Xmslertr8%3D

    Article  PubMed  CAS  Google Scholar 

  2. GF Strippoli C Manno FP Schena (2003) ArticleTitleAn “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism Am J Kidney Dis 41 1129–39 Occurrence Handle12776264 Occurrence Handle10.1016/S0272-6386(03)00344-5 Occurrence Handle1:CAS:528:DC%2BD3sXkvFOisL8%3D

    Article  PubMed  CAS  Google Scholar 

  3. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003;CD003965

  4. J Barratt J Feehally (2005) ArticleTitleIgA nephropathy J Am Soc Nephrol 16 2088–97 Occurrence Handle15930092 Occurrence Handle10.1681/ASN.2005020134 Occurrence Handle1:CAS:528:DC%2BD2MXms1egs7g%3D

    Article  PubMed  CAS  Google Scholar 

  5. J Floege F Eitner (2005) ArticleTitlePresent and future therapy options in IgA-nephropathy J Nephrol 18 354–61 Occurrence Handle16245237 Occurrence Handle1:CAS:528:DC%2BD28**sl2ntg%3D%3D

    PubMed  CAS  Google Scholar 

  6. Sakai H. The Special Study Group on Progressive Glomerular Disease, Ministry of Health, Labor and Welfare of Japan, 1999 report (in Japanese)

  7. Y Tomino H Sakai (2003) ArticleTitleClinical guidelines for immunoglobulin A (IgA) nephropathy in Japan. 2nd version Clin Exp Nephrol 7 93–7 Occurrence Handle14586726 Occurrence Handle10.1007/s10157-003-0232-4

    Article  PubMed  Google Scholar 

  8. P Juni DG Altman M Egger (2001) ArticleTitleSystematic reviews in health care: assessing the quality of controlled clinical trials BMJ 323 42–6 Occurrence Handle11440947 Occurrence Handle10.1136/bmj.323.7303.42 Occurrence Handle1:STN:280:DC%2BD3Mzos1OltQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  9. S Hollis F Campbell (1999) ArticleTitleWhat is meant by intention to treat analysis? Survey of published randomised controlled trials BMJ 319 670–4 Occurrence Handle10480822 Occurrence Handle1:STN:280:DyaK1MvhtVaqsQ%3D%3D

    PubMed  CAS  Google Scholar 

  10. KF Schulz I Chalmers RJ Hayes DG Altman (1995) ArticleTitleEmpirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 408–12 Occurrence Handle7823387 Occurrence Handle10.1001/jama.273.5.408 Occurrence Handle1:STN:280:DyaK2M7itlOitA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  11. AR Jadad RA Moore D Carroll C Jenkinson DJ Reynolds DJ Gavaghan et al. (1996) ArticleTitleAssessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1–12 Occurrence Handle8721797 Occurrence Handle10.1016/0197-2456(95)00134-4 Occurrence Handle1:STN:280:DyaK28zgvVCmug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  12. N Mantel W Haenszel (1959) ArticleTitleStatistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 719–48 Occurrence Handle13655060 Occurrence Handle1:STN:280:DyaG1M%2FosVOhtQ%3D%3D

    PubMed  CAS  Google Scholar 

  13. JL Fleiss (1986) ArticleTitleAnalysis of data from multiclinic trials Control Clin Trials 7 267–75 Occurrence Handle3802849 Occurrence Handle10.1016/0197-2456(86)90034-6 Occurrence Handle1:STN:280:DyaL2s7gsVaksA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  14. R DerSimonian N Laird (1986) ArticleTitleMeta-analysis in clinical trials Control Clin Trials 7 177–88 Occurrence Handle3802833 Occurrence Handle10.1016/0197-2456(86)90046-2 Occurrence Handle1:STN:280:DyaL2s7gsVamtA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  15. CB Begg M Mazumdar (1994) ArticleTitleOperating characteristics of a rank correlation test for publication bias Biometrics 50 1088–101 Occurrence Handle7786990 Occurrence Handle10.2307/2533446 Occurrence Handle1:STN:280:DyaK2Mzgs1GrtQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  16. Y Ueda S Tojo M Hatano T Furukawa K Yoshinaga Y Kinoshita et al. (1979) ArticleTitleClinical effects of dipyridamole (Persantin) on nephrotic syndrome – multiclinic double blind test (in Japanese) Nippon **zo Gakkai Shi 21 1171–83 Occurrence Handle396401 Occurrence Handle1:STN:280:DyaL3c7mtlCgtQ%3D%3D

    PubMed  CAS  Google Scholar 

  17. S Tojo M Narita T Miyahara O Sakai J Ohno N Soeda et al. (1985) ArticleTitleA double-blind controlled study of trimetazidine dihydrochloride and placebo in patients with chronic glomerulonephritis – multi-clinical study (in Japanese) ** to Toseki (Kidney and Dialysis) 19 1367–80

    Google Scholar 

  18. M Yagame Y Tomino M Miura T Suga M Endoh Y Nomoto et al. (1986) ArticleTitleClinical effect of dipyridamole in patients with IgA nephropathy Tokai J Exp Clin Med 11 329–33 Occurrence Handle2960035 Occurrence Handle1:STN:280:DyaL1c%2FktlGnsg%3D%3D

    PubMed  CAS  Google Scholar 

  19. S Tojo N Honda M Shibata M Narita T Miyahara M Sakai et al. (1986) ArticleTitleA double-blind controlled study of dilazep and placebo in patients with chronic glomerulonephritis – multi-clinical study (in Japanese) ** to Toseki (Kidney and Dialysis) 20 289–313

    Google Scholar 

  20. MK Chan SY Kwan KW Chan CK Yeung (1987) ArticleTitleControlled trial of antiplatelet agents in mesangial IgA glomerulonephritis Am J Kidney Dis 9 417–21 Occurrence Handle3555016 Occurrence Handle1:STN:280:DyaL2s3htVWhsA%3D%3D

    PubMed  CAS  Google Scholar 

  21. S Tojo M Narita M Hatano T Miyahara N Honda Y Orita et al. (1987) ArticleTitleA double-blind controlled study of dipyridamole-perlongets and placebo in patients with chronic glomerulonephritis – multi-clinical study (in Japanese) ** to Toseki (Kidney and Dialysis) 22 751–76

    Google Scholar 

  22. S Camara JP de la Cruz MA Frutos P Sanchez E Lopez de Novales E Sanchez et al. (1991) ArticleTitleEffects of dipyridamole on the short-term evolution of glomerulonephritis Nephron 58 13–6 Occurrence Handle1857478 Occurrence Handle1:STN:280:DyaK3Mzht1Giuw%3D%3D

    PubMed  CAS  Google Scholar 

  23. KT Woo GS Lee YK Lau GS Chiang CH Lim (1991) ArticleTitleEffects of triple therapy in IgA nephritis: a follow-up study 5 years later Clin Nephrol 36 60–6 Occurrence Handle1934661 Occurrence Handle1:STN:280:DyaK38%2FjsFyjsQ%3D%3D

    PubMed  CAS  Google Scholar 

  24. GSL Lee HL Choong GSC Chiang KT Woo (1997) ArticleTitleThree-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment Nephrology 3 117–21 Occurrence Handle1:CAS:528:DyaK2s**sFaht7s%3D

    CAS  Google Scholar 

  25. KT Woo RP Edmondson HK Yap AY Wu GS Chiang EJ Lee et al. (1987) ArticleTitleEffects of triple therapy on the progression of mesangial proliferative glomerulonephritis Clin Nephrol 27 56–64 Occurrence Handle3549083 Occurrence Handle1:STN:280:DyaL2s7mtVWltA%3D%3D

    PubMed  CAS  Google Scholar 

  26. FP Schena M Montenegro V Scivittaro (1990) ArticleTitleMeta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease) Nephrol Dial Transplant 5 Suppl 1 47–52 Occurrence Handle2151741 Occurrence Handle1:STN:280:DyaK3MzmtVahsA%3D%3D

    PubMed  CAS  Google Scholar 

  27. L Nolin M Courteau (1999) ArticleTitleManagement of IgA nephropathy: evidence-based recommendations Kidney Int Suppl 70 S56–62 Occurrence Handle10369196 Occurrence Handle10.1046/j.1523-1755.1999.07008.x Occurrence Handle1:STN:280:DyaK1M3psFyksg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  28. L Smeeth A Haines S Ebrahim (1999) ArticleTitleNumbers needed to treat derived from meta-analyses – sometimes informative, usually misleading BMJ 318 1548–51 Occurrence Handle10356018 Occurrence Handle1:STN:280:DyaK1M3osVGqsg%3D%3D

    PubMed  CAS  Google Scholar 

  29. K Takehara A Igarashi Y Ishibashi (1990) ArticleTitleDipyridamole specifically decreases platelet-derived growth factor release from platelets Pharmacology 40 150–6 Occurrence Handle2139727 Occurrence Handle1:CAS:528:DyaK3cXhslajsbc%3D Occurrence Handle10.1159/000138653

    Article  PubMed  CAS  Google Scholar 

  30. M Nagase H Kumagai N Honda (1984) ArticleTitleSuppression of proteinuria by dipyridamole in rats with aminonucleoside nephropathy Ren Physiol 7 218–26 Occurrence Handle6473895 Occurrence Handle1:CAS:528:DyaL2cXlt1aktLs%3D Occurrence Handle10.1159/000172941

    Article  PubMed  CAS  Google Scholar 

  31. T Gohda Y Makita T Shike K Funabiki S Horikoshi I Shirato et al. (2000) ArticleTitleEffect of dilazep hydrochloride, an antiplatelet agent, on the proliferation of cultured mouse glomerular mesangial cells Nephron 84 90–1 Occurrence Handle10644919 Occurrence Handle10.1159/000045549 Occurrence Handle1:CAS:528:DC%2BD3cXhvFOnsrs%3D

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General Internal Medicine, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

    Yoshinori Taji & Takeshi Morimoto

  2. Department of Nephrology, Saiseikai Nakatsu Hospital, Osaka, Japan

    Takashi Kuwahara

  3. Department of Surgery, Soseikai General Hospital, Kyoto, Japan

    Satoru Shikata

Authors
  1. Yoshinori Taji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Kuwahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoru Shikata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Morimoto.

About this article

Cite this article

Taji, Y., Kuwahara, T., Shikata, S. et al. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 10, 268–273 (2006). https://doi.org/10.1007/s10157-006-0433-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-006-0433-8

Key words

Search

Navigation